Trials / Recruiting
RecruitingNCT06892379
A Study of HS-20110 in Participants With Advanced Solid Tumors
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20110 in Participants With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 475 (estimated)
- Sponsor
- Hansoh BioMedical R&D Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-20110 (Phase Ia：Dose escalation ) | HS-20110 for IV infusion of various dose strengths administered in 21 day dosing cycles |
| DRUG | HS-20110 (Phase Ib:Dose expansion ) | The recommended dose from the dose-escalation stage and other potential doses will be further explored |
Timeline
- Start date
- 2025-02-26
- Primary completion
- 2026-12-31
- Completion
- 2027-09-30
- First posted
- 2025-03-24
- Last updated
- 2026-04-08
Locations
6 sites across 2 countries: United States, China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06892379. Inclusion in this directory is not an endorsement.